SCIENCE NEWS
Less Invasive Techniques Help Manage Complications of Severe Pancreatic Disease
The use of combined treatments for severe acute pancreatitis is safe and effective in managing the disease, resulting in shorter hospitalizations and fewer radiological procedures than standard therapy, according to a study. [Press release from EurekAlert! discussing online prepublication in Clinical Gastroenterology and Hepatology]
Researchers Take Step Forward in Diabetes Study
Researchers are studying a solution they believe will improve the quantity and quality of isolated human pancreatic islet cells. The harvested cells can then be transplanted into the livers of patients with type 1 diabetes, enabling them to produce their own insulin. [Baylor Health Care System Press Release]
|
|
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)
DIABETES
Augmented Glucose-Induced Insulin Release in Mice Lacking Go2, but not Go1 or Gi Proteins
Researchers show that one of the two splice variants of Go, Go2, is a key player in the control of glucose-induced insulin secretion by beta cells. [Proc Natl Acad Sci U S A]
Genetic Inducible Fate Mapping in Larval Zebrafish Reveals Origins of Adult Insulin-Producing Beta Cells
Researchers report on using Cre-based fate mapping to indelibly label pancreatic Notch-responsive cells (PNCs) at larval stages and follow their fate in the adult pancreas. They show that the PNCs represent a population of progenitors that can differentiate to multiple lineages, including adult ductal cells, centroacinar cells and endocrine cells. [Development ]
Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans
The glucagon-like peptide receptor agonist exenatide prevented prednisolone-induced glucose intolerance and islet-cell dysfunction in healthy humans. Incretin-based therapies should be explored as a potential strategy to prevent steroid diabetes. [Diabetes Care]
Paracrine Signaling Loops in Adult Human and Mouse Pancreatic Islets: Netrins Modulate Beta Cell Apoptosis Signaling via Dependence Receptors
Results highlight the large number of potential islet growth factors and point to a context-dependent pro-survival role for netrins in adult beta cells. [Diabetologia]
An Islet-Specific Pulse of TGF-Beta Abrogates CTL Function and Promotes Beta Cell Survival Independent of Foxp3+ T Cells
Researchers show that expression of TGF-beta for just 1 week in inflamed islets of non-obese diabetic mice significantly delays diabetes development. [J Immunol]
Differential Regulation of Endoplasmic Reticulum Stress by Protein Tyrosine Phosphatase 1B and T Cell Protein Tyrosine Phosphatase
Results demonstrate that protein-tyrosine phosphatase 1B (PTP1B) and T cell protein-tyrosine phosphatase (TCPTP) play non-redundant roles in modulating endoplasmic reticulum (ER) stress in pancreatic beta cells and suggest that changes in PTP1B and TCPTP expression may serve as an adaptive response for the mitigation of chronic ER stress. [J Biol Chem]
Metabolomic Analyses Reveal Profound Differences in Glycolytic and Tricarboxylic Acid Cycle Metabolism in Glucose-Responsive and -Unresponsive Clonal Beta Cell Lines
To increase understanding of stimulus-secretion coupling and metabolic processes potentially involved in the pathogenesis of type 2 diabetes, a comprehensive investigation of the metabolic response in the glucose-responsive INS-1 832/13 and glucose-unresponsive INS-1 832/2 beta cell lines was performed. [Biochem J]
PANCREATIC CANCER
miR-301a as an NF-KappaB Activator in Pancreatic Cancer Cells
In this work, researchers investigated whether microRNAs contribute to NF-kappaB activation in pancreatic cancer. [EMBO J]
Lineage Tracing Reveals the Dynamic Contribution of Hes1+ Cells to the Developing and Adult Pancreas
The study clarifies the roles of Notch and Hes1 in the developing and adult pancreas, and open new avenues to study Notch signaling in this and other tissues. [Development]
DNA Mismatch Repair Gene Polymorphisms Affect Survival in Pancreatic Cancer
DNA mismatch repair gene variants may have potential value as prognostic markers for overall survival in pancreatic cancer patients. [Oncologist]
Endoscopic and Percutaneous Drainage of Symptomatic Walled-Off Pancreatic Necrosis Reduces Hospital Stay and Radiographic Resources
For patients with symptomatic walled-off pancreatic necrosis, combined modality therapy provided a more effective and safer management technique, resulting in shorter hospitalizations and fewer radiologic procedures than standard percutaneous drainage. [Clin Gastroenterol Hepatol]
Glutamate Increases Pancreatic Cancer Cell Invasion and Migration via AMPA Receptor Activation and Kras-MAPK Signaling
Researchers show that glutamate-mediated alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation increases invasion and migration of pancreatic cancer cells via activation of the classical MAPK pathway. [Int J Cancer]
|
|
INDUSTRY NEWS
Boehringer Ingelheim and Eli Lilly and Company Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide
Boehringer Ingelheim and Eli Lilly and Company announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. [Boehringer Ingelheim GmbH Press Release]
Neogenix Oncology® Receives Additional Federal Grant, Bringing Total Award to Over $730,000
Neogenix Oncology, Inc. announced that the company has been awarded an additional grant under the Qualifying Therapeutic Discovery Project Program, bringing the total amount received by Neogenix Oncology under this federal program to $733,437.74. [Business Wire]
Merck Announces FDA Acceptance of New Drug Application for an Investigational Extended-Release Formulation of JANUMET® (sitagliptin/metformin HCI) for Type 2 Diabetes
Merck announced that the New Drug Application for the Company’s investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). [Merck & Co., Inc. Press Release]
DARA BioSciences Announces Additional Details From Phase I Clinical Study of DB959 for the Treatment of Type 2 Diabetes
DARA BioSciences, Inc. provided additional details from the recently completed Phase I clinical study for DB959, its PPAR (peroxisome proliferator activated receptor) delta/gamma agonist, an oral drug in development for the treatment of type 2 diabetes. [DARA BioSciences, Inc. Press Release]
Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
Lexicon Pharmaceuticals, Inc. announced data from a recently completed clinical trial and mechanistic study of a solid oral dose formulation for LX4211, a dual inhibitor of sodium-glucose co-transporters 1 and 2. [Lexicon Pharmaceuticals, Inc. Press Release]
Peregrine Initiates Randomized Phase II Trial of Bavituximab in Pancreatic Cancer
Peregrine Pharmaceuticals, Inc. announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated stage IV pancreatic cancer. [Peregrine Pharmaceuticals, Inc. Press Release]
American Diabetes Association Announces New National Officers and Board Members
The American Diabetes Association is pleased to announce its officers and Board of Directors members for 2011. [American Diabetes Association Press Release]
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
